The Perils of Volatility: Adams Seesaws on Speculation about FDA
This article was originally published in RPM Report
Executive Summary
Adams Respiratory Therapeutics took a wild ride on June 8, with the stock plunging 10% in a matter of minutes. All because of something FDA didn't do.